anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A compound expressed by the formula (Me represents methyl; R represents substituted lower alkyl; dotted line denotes alpha, beta or mixture thereof) or salt thereof. EXAMPLE:K-41.C(29) furfuryl ether sodium salt. USE:An anti-coccidial agent. PREPARATION:For example, a K-41 sodium salt II is dissolved in chloroform and furfuryl alcohol is added. The chloroform is distilled off under reduced pressure. Further furfuryl alcohol is added thereto, dissolved, heated, diluted with chloroform, washed with water and dried and the chloroform is distilled off the afford an oily substance containing the unreacted alcohol. The resultant substance is dissolved in chloroform, passed through a gel column and the unreacted alcohol is removed. Then an ether derivative is eluted with an acetone-containing chloroform and the residue is dissolved into chloroform, followed by washing, solvent removal and crystallization.
Standard of care interventions for the treatment of renal masses using energy ablation will be studied. Data collection can be divided into five basic categories: 1) Patient demographics and relevant history, 2) Renal mass characteristics, 3) Ablation procedure details, 4) Imaging studies, and 5) Patient-reported quality of life.
The invention provides a nanoparticle based on tetrahedral framework nucleic acid, a preparation method thereof and application thereof in treating hydrocephalus, and belongs to the field of biological medicines. The nanoparticle is formed by base complementary pairing of 4 single-stranded DNA; the nucleotide sequences of the 4 single-stranded DNAs are shown as SEQ ID NO.1, SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO. 6. The nano particles can be used as medicines to reduce the expression of SPAK and OSR1 in choroid plexus epithelial cells, and simultaneously down regulate the expression of proteins NKCC1, ATP1a1, KCNJ13 and CLIC6 of which the downstream ion channels are related to cerebrospinal fluid secretion, and inhibit the hypersecretion of cerebrospinal fluid. Meanwhile, the TSOs can inhibit polarization of choroid plexus macrophages from M0 to M1, inhibit secretion of inflammatory cytokines by the macrophages, and relieve choroid plexus inflammation, so that hydrocephalus formation is inhibited. Therefore, the TSOs prepared by the method can effectively inhibit hydrocephalus occurrence and development, and have potential clinical application prospects.
Recent research has emphasized the development of efficient drug delivery systems to facilitate the delivery of biological compounds such as polyphenols via skin absorption. Phytozomes have been employed as carriers of plant compounds in this context Hydrogen bonding between plant polyphenols and the phospholipid phosphate group enables efficient encapsulation of potent compounds for enhanced drug delivery systems. Additionally, the strong affinity of phytosomes for the skin's phospholipids enhances skin absorption. In this study, phytosomes were initially formulated using the thin-layer hydration method After optimizing the synthetic parameters, phytosomes were loaded with Resveratrol and Quercetin for enhanced delivery and skin absorption potential to assess the characteristics of the synthesized phytosomes, tests were conducted to determine particle distribution and size, zeta potential, and examine the microstructure morphology using a scanning electron microscope (SEM). Furthermore, a siloxane gel base was formulated in this study, and the stability of the physicochemical and biological properties of the final prepared nanoformulation was investigated. The results of this study indicated that the formulated phytosomes exhibit optimal characteristics for facilitating high skin penetration of resveratrol and quercetin. A high skin absorption was observed after 60 days of synthesis. Additionally, the base of the siloxane gel can play a significant role in preventing the formation of scars by reducing the passage of water vapor.
The present invention provides novel type IIc Na/Pi cotransporters. These cotransporters are important Pi transporters that are highly expressed during the growth period from the weaning stage to the adult stage. Furthermore, the present invention provides FGF23 and mutants thereof as factors that regulate the expression of type II Na/Pi cotransporters. FGF23 suppresses Pi reabsorption through suppression of type II Na/Pi cotransporter expression in kidneys. Therefore, FGF23 can be used as a target substance for regulating Pi reabsorption in kidneys. The present invention provides important factors for the development of preventive and therapeutic agents for hyperphosphatemia or hypophosphatemia.
Participants will receive a 12-week, Positive Psychology-Motivational Interviewing (PP-MI) intervention. Each week, participants will complete a PP activity and work towards one or more health behavior goals, then complete a phone session with a study trainer. Each weekly session will include PP and goal setting portions. In the PP portion, a study trainer will (a) review the week's PP exercise, (b) discuss the rationale of the next week's PP exercise through a guided review of the PP-MI manual, and (c) assign the next week's PP exercise. Additionally for the goal-setting portion, the trainer will (a) review their goals and health behaviors from the prior week, (b) discuss techniques for improving health behavior adherence (e.g., monitoring physical activity, reading nutrition labels), and (c) set goals for the next week. Finally, participants will receive supplemental text messages throughout the 12 weeks of the intervention and during the initial follow-up period (Week 13-24).
The Adopting and Demonstrating the Adaptation of Prevention Techniques project (referred to as ADAPTATION throughout this protocol) responds to concerns from the field that existing interventions do not address the HIV prevention needs of diverse and often unstudied populations. This project will pilot test a step-by-step guide for community-based organizations to engage in evidence-based adaptation of interventions previously shown to be effective in research settings for use in real world applications. The main purpose of this program is to improve understanding of the processes needed for adapting evidence-based behavioral interventions to fit new conditions or populations and to pilot CDC-developed draft guidance for adaptation. The second purpose of the program is to increase the number of effective behavioral HIV prevention interventions for 18-24 year old sero-positive men of color who have sex with other men (MSM of color).

Harlem United Community AIDS Center is one of five sites originally funded through Program Announcement 04064 and selected to receive a supplement to conduct adaptation activities. Under Program Announcement 04064, Harlem United, a community-based organization with over 16 years of experience providing quality HIV services to the Harlem and South Bronx communities, was funded to implement a multi-faceted, HIV prevention program. The program combines rapid testing, access to care, and an evidenced-based, group-level behavioral intervention (i.e., Healthy Relationships) for sero-positive, heterosexual men and women of color. Healthy Relationships is a five-session, small group-level intervention for persons living with HIV/AIDS that promotes the development of decision-making and problem-solving skills that enable participants to make informed and safe decisions about disclosure and behaviors. Preliminary evaluation efforts suggest that this service model is effective in reducing risk behaviors among the general population, but its appropriateness and effectiveness for specific sub-populations has yet to be fully demonstrated. The original research for Healthy Relationships was conducted in Atlanta, Georgia. Approximately half of the participants identified as gay and the study population had a mean age of 40 years. Harlem United will adapt the Healthy Relationships intervention for young sero-positive MSM of color between the ages of 18-24 who reside in Harlem, New York. Further adaptation also may include adding decision-making for disclosure with needle sharing partners.

The goal of Harlem United's ADAPTATION project is to evaluate efforts to adapt and implement the Healthy Relationships intervention for young sero-positive MSM of color by: 1) documenting the resources and activities required to adapt and implement the Healthy Relationships intervention model for young sero-positive MSM of color; 2) optimizing service delivery; 3) measuring the effectiveness of the newly-adapted intervention; and 4) assessing CDC's guidance for adapting effective behavioral interventions for new populations.
Internet treatment with therapist support means that measurements are collected through the Internet. Participants are recruited from a specialized pain clinic for chronic pain. All patients with sleep complaints (Insomnia Severity Index \> 14) at their first visit through 2016-01-01 to 2017-07-31 are asked for participation via mail. Volunteers sign informed consent and undergo a online screening. If matching the inclusion criteria, they are contacted for a telephone interview. Subjects are assessed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criterion for insomnia disorder, M.I.N.I. (screening for psychiatric comorbidity) and the other inclusion/exclusion criteria. The treatment, that is designed to be short, concise and user friendly as it is meant to be usable as an adjunct treatment to other main interventions for chronic pain. The treatment lasts for five weeks and focuses on the most potent CBT technics for insomnia; sleep restriction and stimulus control.

Randomization is conducted by university staff not otherwise involved in this study. Participants have equal chance to be allocated to ether CBT or applied relaxation techniques (active controls). The relaxation treatment lasts for the same amount of time (five weeks) and is designed to require similar weekly effort. Both groups fill in sleep diaries every week and weekly feedback is provided by master students supervised by clinical psychologists.

The overall hypothesis is that CBT leads to greater symptom reduction (according to the Insomnia Severity Index) compared to applied relaxation techniques.
In accordance with the present invention, there is provided an example of a novel class of nuclear receptor(s), termed the steroid X receptor (SXR). SXR is expressed almost exclusively in the liver, the primary site of xenobiotic and steroid catabolism. Unlike classical steroid receptors, SXR heterodimerizes with RXR and binds to directly repeated sequences related to the half-site, AGTTCA. SXR can activate transcription through response elements found in some steroid inducible P450 genes in response to a wide variety of natural and synthetic steroid hormones, including antagonists such as PCN-ideal properties for a "steroid sensing receptor" which mediates the physiological effect(s) of hormones. SXR represents the first new class of steroid receptors described since the identification of the mineralocorticoid receptor ten years ago. Also provided according to the invention are nucleic acid sequences encoding the above-identified receptors, as well as constructs and cells containing same, and probes derived therefrom. Furthermore, it has also been discovered that a wide variety of substrates modulate the transcription activating effects of invention receptors.
Provided is secreted Frizzled-Related Protein 3 (sFRP3), or a therapeutically effective fragment or derivative thereof, for use as a medicament for accelerating wound healing. The wound may be a skin wound. The wound may be a surgical wound. The medicament may be a topical medicament. The medicament may be for local injection. The medicament may increase the rate of contraction of a treated wound. Also provided is a method of accelerating wound healing, the method comprising providing a therapeutically effective amount of sFRP3, or a therapeutically effective fragment or derivative thereof, to a site where wound healing is to be accelerated.
The invention provides a gene engineering bacterium of the expression of soluble FGF-21. The bacterium contains Escherichia coli DH5 alpha carrying the plasmid pET32a(+)-PT7lac-TrxA-6xHis-FGF-21 and Escherichia coli BL21(DE3) carrying the plasmids pET32a(+)-PT7lac-TrxA-6xHis-FGF-21 and pTf16-ParaB-tig. The invention also provides a gene engineering bacterium containing the FGF-21 sequence and a construction method of the gene engineering bacterium of the expression of soluble FGF-21. The invention also provides a method for producing FGF-21 by using the gene engineering bacterium, wherein expression molecular chaperone tig is used and the self-induced culture method is adopted to obtain soluble FGF-21. The invention also provides an application of the gene engineering bacterium for producing FGF-21 in the preparation of medicines for curing diabetes. The purification process is simple, is easy to operate and has low production cost; and the expression product has biological activities to reduce blood sugar and regulate lipid metabolism.
BACKGROUND: Chorea is a common movement disorder in children, requiring thorough clinical assessment and appropriate tests for etiological diagnosis. Early identification of treatable conditions can lead to effective treatment, reducing morbidity and improving quality of life.
OBJECTIVE: To describe the clinical, demographic, and epidemiological characteristics of children and adolescents diagnosed with chorea.
METHODS: A retrospective cross-sectional study of pediatric patients treated in a fourth-level hospital in Bogotá, Colombia, from January 2008 to January 2022.
RESULTS: 81 patients with chorea were found. The most frequent etiologies were rheumatic fever (50.6 %), vascular chorea (29.3 %), and chorea secondary to lupus (11.1 %). Patients with chorea secondary to rheumatic fever (Sydenham's chorea) were older compared to other etiologies, 10.36 ± 3.41 years vs 8.29 ± 5.16, p = 0.037. The presence of another movement disorder or abnormalities during the physical examination suggests a different etiology from rheumatic fever. Moreover, the presence of psychiatric symptoms was similar in all etiologies. However, a correlation between age and psychiatric symptoms was observed with an odds ratio of 1.14 95 % CI 1.02-1.29 per year.
CONCLUSIONS: Red flags in Sydenham's chorea suggesting an alternate etiology are younger age, the presence of other abnormal movements or other findings in the neurological exam or in the magnetic resonance imaging. No significant statistical differences were found between the etiologies with the presence of neuro-psychiatric manifestations. Nevertheless, these manifestations are very frequent in abnormal movements. This study evidenced the positive correlation between age and the presence of psychiatric symptoms.
PURPOSE: To properly classify lips by performing classification while the shape represented by the length of the lips in proportion to the width of the face and the side of lips represented by the product of the absolute lip width and the absolute lip length are used as indices. CONSTITUTION: To classify lips, the shape of lips, in particular the relative lip length to the width of the face, and the area of lips, in particular the product of the absolute lip length and lip width are used as indices. The relative lip length does not signify a length as absolute numerical value, but a lip length in proportion to the width of the face-more concretely, for example a one represented by the absolute lip length relative to the length between the left and right jaw bones. On the contrary, the size is typically represented by the area more simply, it is calculated as the product of the absolute lip width and absolute lip length. That is, the value c×a may be taken. This is because the lips having good balance with the face keep always the same size irrespective of the shape of the lips.
The present invention comprises analogs of the CA1A2X motif of the protein Ras that is modified by farnesylation in vivo. These CA1A2X analogs inhibit the farnesyl-protein transferase and the farnesylation of certain proteins.  Furthermore, these CA1A2X analogs differ from those previously described as inhibitors of farnesyl-protein transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. The compounds of the instant invention also incorporate a cyclic amine moiety in the A2 position of the motif.  Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production.
Multivariate disease mapping is important for public health research, as it provides insights into spatial patterns of health outcomes. Geostatistical methods that are widely used for mapping spatially correlated health data encounter challenges when dealing with spatial count data. These include heterogeneity, zero-inflated distributions and unreliable estimation, and lead to difficulties when estimating spatial dependence and poor predictions. Variability in population sizes further complicates risk estimation from the counts. This study introduces multivariate Poisson cokriging for predicting and filtering out disease risk. Pairwise correlations between the target variable and multiple ancillary variables are included. By means of a simulation experiment and an application to human immunodeficiency virus incidence and sexually transmitted diseases data in Pennsylvania, we demonstrate accurate disease risk estimation that captures fine-scale variation. This method is compared with ordinary Poisson kriging in prediction and smoothing. Results of the simulation study show a reduction in the mean square prediction error when utilizing auxiliary correlated variables, with mean square prediction error values decreasing by up to 50%. This gain is further evident in the real data analysis, where Poisson cokriging yields a 74% drop in mean square prediction error relative to Poisson kriging, underscoring the value of incorporating secondary information. The findings of this work stress on the potential of Poisson cokriging in disease mapping and surveillance, offering richer risk predictions, better representation of spatial interdependencies, and identification of high-risk and low-risk areas.
PURPOSE:To make possible easily a desired analysis by bringing a labeling antigen (antibody) and a carrier carrying an antigen (antibody) as a solid phase into reaction and separating the reactive liquid to an immune complex and the remaining labeling antibody in accordance with the information on the carrier detected from the reactive liquid. CONSTITUTION:The reactive liquid 13 in which the immune complex and the remaining antibody are mixed is introduced through a needle 12 into a flow cell 11. The scattered light and fluorescence by laser light 14 of the immune complex and remaining and remaining labeling antibody flowing in the needle 12 are detected by detectors 15, 16, by which a sightgramis obtd. from the parameter thereof. The recognition in the measurement of the immune complex and the remaining labeling antibody from the difference in the size of the particles thereof is made easy if the latex immunoassay is used by using the flow sight meter in the above-mentioned manner. The variance in the size and shape of the immune complex is fairly decreased and the analysis with high accuracy is made possible.
PROBLEM TO BE SOLVED: To obtain a new compound useful as an intermediate for synthesizing a raw material compound providing a parallel synthetic method for producing camptothecin and its analogue having antileukemic and anti-tumor characteristics in a high yield. SOLUTION: This new compound is represented by formula I (R6 is a lower alkyl; Y is Cl or H; Z is a halogen), formula II (R7 is a lower alkyl) or formula III (R and R8 are each a lower alkyl), e.g. 6-chloro-4-iodo-2-methoxy-3- pyridinecarboxyaldehyde. The compound of formula I is obtained by halogenating a compound of formula IV. The compound of formula II is obtained by reducing the compound of formula I with an alcoholic acidic medium in the presence of a trialkylsilane. The compound of formula III is obtained by litiation of C-4-position of the compound of formula II and then reacting the resultant compound with a compound such as an alkali α-ketobutyrate. A compound of formula V obtained by cyclization of the compound of formula III is a compound useful for producing camptothecin, etc.
PURPOSE: A composition containing Brandisia hancei Hook. f. extract or fraction thereof is provided to suppress aldose reductaase activity and to prevent and treat diabetes complication. CONSTITUTION: A pharmaceutical composition for preventing and treating diabetes complication contains Brandisia hancei Hook. f. extract as an active ingredient. The extract is prepared from branches, stems, or roots of Brandisia hancei Hook. f. using water, low alcohol of C1-C2, mixture solvent or water soluble alcohol. The pharmaceutical composition for preventing and treating diabetes complication contains a fraction prepared from the extract using organic solvent.
The objective is to determine whether or not injured muscles that are subject to icing after eccentrically damaging exercise recover their strength quicker and/or have less muscle soreness than those that do not receive any icing treatment after damaging exercise and if any differences in effectiveness between two icing protocols exist. Baseline measures of peak torque of the dominant arm's elbow flexor muscles will be measured by concentric and isometric contractions prior to participants undergoing eccentric muscle damaging exercise. Participants will be randomly assigned into 3 different experimental groups of approximately 15 participants each. The first group will begin "Icing Protocol 1" at time 0 (or as close to). The second group will begin "Icing Protocol 2" six hours after their initial eccentric muscle damaging exercise. The remaining group will not receive any icing treatment; they are the control group. Participants will be brought back into the lab at specific post-exercise times (0h, 24h, 48h, 96h, and 7 days) to complete peak torque measures as they did with baseline measures prior to eccentric muscle damage. Measures of delayed onset muscle soreness (DOMS) will also be taken at baseline and during scheduled follow up times for participants.
PURPOSE:To obtain an ophthalmic pharmaceutical composition, containing 15-keto-prostaglandins and a sympathomimetic agent as active ingredients, having excellent intraocular hypotensive action and reduced in side effects. CONSTITUTION:An ophthalmic pharmaceutical composition is obtained by including (A) 15-keto-prostaglandins or their salts and esters thereof and (B) a sympathomimetic agent, especially epinephrine or phenylephrine as active ingredients. The ingredients are blended in the following amounts. 0.005-2wt.% ingredient (A) and 0.005-20wt.% ingredient (B) at a blending ratio of the ingredients (A) to (B) within the range of (1:0.5)-(1:200). The composition is prepared into the form of a solution, an emulsion, a suspension or a gel, an ophthalmic ointment, etc. The aforementioned composition is effective in treating intraocular hypertension and glaucoma.